• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New Report Reveals Alarming Decline in Women's Cancer Testing Worldwide

    1/21/25 8:00:00 AM ET
    $HOLX
    Medical Electronics
    Health Care
    Get the next $HOLX alert in real time by email

    Women's cancer testing has declined globally, according to the latest Hologic Global Women's Health Index, one of the largest collections of data on women's health and well-being.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121461870/en/

    Hologic, Inc. (NASDAQ:HOLX), a leading women's health innovator, partners with Gallup to create the Index. Now in its fourth year, the Index raises new concerns about declining trends in women's health. For the first time in the history of the Index, women's cancer testing declined: Only 10% of women surveyed worldwide said they were tested for any type of cancer in the past year, down two percentage points from the first two years of the Index.

    This year's Index will be released today during an event convened by Goals House, a community focused on driving progress toward the United Nations (UN) Sustainable Development Goals (SDGs) alongside the World Economic Forum in Davos, Switzerland. The event will feature a panel including Dr. Natalia Kanem, Executive Director of the United Nations Population Fund (UNFPA), Dr. Sania Nishtar, CEO, Gavi, The Vaccine Alliance and Elissa Miolene, Global Development Reporter, Devex.

    "Today's data reveal a worsening trend in women's health," said Stephen P. MacMillan, Chairman, President and CEO of Hologic. "The shocking decline in cancer testing is a wake-up call. Business as usual is not working. Innovative strategies and collaborative efforts are needed to make sustained improvements in women's health and well-being around the world."

    Key findings from this year's Index:

    • Cancer Screening Among Women Declined: Only 10% of women said they underwent any type of cancer testing in the past year, reflecting a decrease of two percentage points from the first two years of the survey.
    • Women Are Struggling More to Meet Basic Needs: A staggering 38% of women reported being unable to afford food at some point in the past year, marking the highest level of food insecurity in nearly two decades. And 32% of women said they could not afford adequate shelter.
    • More Women Are Worried and Sad: More women reported feeling worried (42%) and sad (30%) compared to Year 1 of the Index. And over one third (35%) said they felt unsafe in their communities.
    • Ongoing Physical Pain and Health Issues: 34% of women reported experiencing significant pain the previous day, while 26% indicated that health problems impacted their ability to engage in everyday activities.
    • HIV Testing Rates for Women Are Alarmingly Low: The Index assessed women's HIV testing for the first time and found concerning disparities: Less than 0.5% of women were tested in certain countries, primarily those in the Middle East and North Africa, and no country scored above 41%. Globally, the percentage is much lower. Just 6% of women — regardless of whether they visited a healthcare professional or were tested for STIs — said they were tested for HIV in the past year.
    • Signs of Hope — Some Countries Are Making Progress: 28 countries saw meaningful increases in their Index scores since the first year of the Index, including Kazakhstan, Kenya, Poland and Venezuela.

    The Index assigns a women's health score to each country or territory based on survey responses on five dimensions of health. Overall, the world scored 53 out of 100 on the Index in Year 4, reflecting no significant change since the Index started.

    Taiwan led the world for the fourth consecutive year, scoring 68 out of a possible 100. Other top scores went to Kuwait (67), Austria (66) and Switzerland (65). The lowest scores went to Afghanistan (30), the Democratic Republic of Congo (34) and Chad (35). The United States scored 60 – on par with New Zealand (60) and Lithuania (60) – and fell seven places from its ranking in the third year of the Index to 37 out of 142 countries and territories.

    The Index fills a critical gap in knowledge about the health, safety and well-being of women worldwide. Based on interviews with more than 146,000 women and men in 142 countries and territories, it represents the voices of 97% of the world's women and girls aged 15 and older.

    To see the full Index and related resources, visit WomensHealthIndex.com.

    About Hologic, Inc.

    Hologic, Inc. is a global leader in women's health, dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. For more information on Hologic, visit www.hologic.com and connect with us on LinkedIn, Facebook, X, Instagram and YouTube.

    Hologic and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

    About Gallup

    Gallup delivers analytics and advice to help leaders and organizations solve their most pressing problems. Combining more than 80 years of experience with its global reach, Gallup knows more about the attitudes and behaviors of employees, customers, students and citizens than any other organization in the world.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250121461870/en/

    Investor Contact

    Michael Watts

    Corporate Vice President, Investor Relations

    (+1) 858.410.8514

    [email protected]

    Media Contact

    Bridget Perry

    Senior Director, Corporate Communications

    (+1) 508.263.8654

    [email protected]

    Get the next $HOLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HOLX

    DatePrice TargetRatingAnalyst
    1/12/2026Buy → Hold
    Argus
    1/5/2026$78.00Outperform → In-line
    Evercore ISI
    11/21/2025$79.00Outperform → Neutral
    BNP Paribas Exane
    10/7/2025$78.00In-line → Outperform
    Evercore ISI
    8/18/2025$80.00Hold → Buy
    Argus
    8/6/2025$87.00Sector Perform → Outperform
    RBC Capital Mkts
    7/9/2025$80.00Neutral → Buy
    Citigroup
    5/27/2025Hold
    Needham
    More analyst ratings

    $HOLX
    SEC Filings

    View All

    SEC Form 8-K filed by Hologic Inc.

    8-K - HOLOGIC INC (0000859737) (Filer)

    2/6/26 8:00:17 AM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form 10-Q filed by Hologic Inc.

    10-Q - HOLOGIC INC (0000859737) (Filer)

    1/29/26 4:08:35 PM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form DEFA14A filed by Hologic Inc.

    DEFA14A - HOLOGIC INC (0000859737) (Filer)

    1/29/26 4:04:16 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hologic downgraded by Argus

    Argus downgraded Hologic from Buy to Hold

    1/12/26 9:02:06 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Hologic from Outperform to In-line and set a new price target of $78.00

    1/5/26 8:48:38 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic downgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane downgraded Hologic from Outperform to Neutral and set a new price target of $79.00

    11/21/25 8:06:35 AM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Madaus Martin D bought $300,760 worth of shares (5,445 units at $55.24) (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    5/9/25 4:39:33 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    1.5 Billion Women Miss Essential Preventive Tests, Despite Uptick in Global Screening Rates

    Fifth edition of Hologic Global Women's Health Index reveals over half of women worldwide weren't tested for key conditions in the past year Hologic and Gallup convene experts to discuss closing gaps in screening access Global women's health leader Hologic, Inc. (NASDAQ:HOLX) today released data showing that while testing for some health conditions has risen among women globally, a vast screening gap remains. Over half of women and girls aged 15 and older — an estimated 1.5 billion women — were not tested for cancer, high blood pressure, diabetes or sexually transmitted infections (STIs) in the past year. This press release features multimedia. View the full release here: https://www.b

    3/17/26 8:00:00 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio

    Expanded FDA approval across multiple cervical cancer screening modalities supports clinical flexibility and provider choice Hologic, Inc. (NASDAQ:HOLX) announced today that its Aptima® HPV Assay received FDA approval for clinician-collected HPV primary screening. Hologic's human papillomavirus (HPV) test is the only FDA-approved mRNA-based assay, designed specifically to detect infections most likely to lead to cervical cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126336815/en/ Screening for cervical cancer is critically important to women's health. In the United States, it is estimated that in 2026, approximatel

    2/4/26 8:15:00 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic Announces Financial Results for First Quarter of Fiscal 2026

    – Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases (9.2%), Non-GAAP Diluted EPS of $1.04 Up 1.0% – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal first quarter ended December 27, 2025. The Company reported revenue of $1,047.8 million, GAAP diluted EPS of $0.79, and non-GAAP diluted EPS of $1.04. Highlights The Company has scheduled for February 5, 2026 a special meeting of stockholders to vote on adopting the merger agreement with funds managed by Blackstone and TPG, and related matters. Revenue of $1,047.8 million increased 2.5% for the quarter, or 1.3% on a constant currency basis. Total organic reve

    1/29/26 4:02:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 29, 2024 - FDA Roundup: October 29, 2024

    For Immediate Release: October 29, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA responded to objections on the agency’s final rule that removed the authorized food contact uses of most phthalates because industry abandoned these uses. The FDA evaluated the objections and concluded that they did not provide a basis for mod

    10/29/24 3:30:19 PM ET
    $HOLX
    Medical Electronics
    Health Care

    February 2, 2024 - FDA Roundup: February 2, 2024

    For Immediate Release: February 02, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a safety communication to warn consumers, health care providers, and health care facilities not to use certain Cardinal Health Monoject luer-lock and enteral syringes. Dimensional changes made to the syringes, when used with syringe pump

    2/2/24 3:58:21 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel Liddy Anne M. covered exercise/tax liability with 185 shares, decreasing direct ownership by 0.66% to 28,052 units (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    3/2/26 4:30:37 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Director Wendell Amy Mcbride was granted 3,190 shares, increasing direct ownership by 14% to 25,784 units (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    3/2/26 4:29:04 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Director Stewart Stacey D. was granted 3,190 shares, increasing direct ownership by 62% to 8,358 units (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    3/2/26 4:27:37 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Leadership Updates

    Live Leadership Updates

    View All

    Biote Announces CEO Retirement and Succession Plan

    Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

    1/30/25 4:10:00 PM ET
    $BTMD
    $HOLX
    $MYGN
    Medicinal Chemicals and Botanical Products
    Health Care
    Medical Electronics
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    CellMax Life Announces Expansion of Company Board With Leading Industry Experts

    Renowned industry experts join to aid in preparation around premarket approval for FirstSight SUNNYVALE, Calif., April 6, 2023 /PRNewswire-PRWeb/ -- CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the appointment of Stanley N. Lapidus (Stan) as an advisory board member and Ronnie (Ron) Andrews as an independent board member. The announcement comes only one month after CellMax Life expanded its GI advisory board with luminaries in the GI arena. "Both Stan and Ron are pioneers in the diagnostics industry, with unique perspectives and proven track records of success," said Atul Sharan, CEO of CellMax Life. Stan is one of t

    4/6/23 9:00:00 AM ET
    $EXAS
    $HOLX
    Medical Specialities
    Health Care
    Medical Electronics

    IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS

    MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders.  "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics.  "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo

    11/11/21 7:26:31 PM ET
    $BEAT
    $GMED
    $GTHX
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Electronics

    $HOLX
    Financials

    Live finance-specific insights

    View All

    Hologic Announces Financial Results for First Quarter of Fiscal 2026

    – Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases (9.2%), Non-GAAP Diluted EPS of $1.04 Up 1.0% – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal first quarter ended December 27, 2025. The Company reported revenue of $1,047.8 million, GAAP diluted EPS of $0.79, and non-GAAP diluted EPS of $1.04. Highlights The Company has scheduled for February 5, 2026 a special meeting of stockholders to vote on adopting the merger agreement with funds managed by Blackstone and TPG, and related matters. Revenue of $1,047.8 million increased 2.5% for the quarter, or 1.3% on a constant currency basis. Total organic reve

    1/29/26 4:02:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic to Announce Financial Results for the First Quarter of Fiscal 2026 on Thursday, January 29, 2026

    Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2026 on Thursday, January 29, after the market closes. As previously announced, in light of Hologic's pending acquisition by Blackstone and TPG, the Company will not be hosting a quarterly conference call or providing financial guidance. About Hologic Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com. SOURCE: Hologic, Inc. View source version on businesswire.com: https://www.businesswire.com/

    1/15/26 7:00:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic Announces Financial Results for Fourth Quarter of Fiscal 2025

    – Revenue of $1,049.5 Million Grows 6.2% – – GAAP Diluted EPS of $0.83 Increases 9.2%, Non-GAAP Diluted EPS of $1.13 Up 11.9% – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal fourth quarter ended September 27, 2025. The Company reported revenue of $1,049.5 million, GAAP diluted EPS of $0.83, and non-GAAP diluted EPS of $1.13. Highlights On October 21, 2025, the Company announced it had entered into a definitive agreement to be acquired by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share (the "Proposed Transaction"). Revenue of $1,049.5 million increased 6.2% for the quarter, or 5.4% in constant currenc

    11/3/25 4:01:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hologic Inc.

    SC 13G/A - HOLOGIC INC (0000859737) (Subject)

    11/14/24 1:28:29 PM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form SC 13G filed by Hologic Inc.

    SC 13G - HOLOGIC INC (0000859737) (Subject)

    2/14/24 10:04:34 AM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form SC 13G/A filed by Hologic Inc. (Amendment)

    SC 13G/A - HOLOGIC INC (0000859737) (Subject)

    2/9/23 11:22:19 AM ET
    $HOLX
    Medical Electronics
    Health Care